Ceramide promotes lytic reactivation of Epstein-Barr virus in gastric carcinoma

• Published in: Journal of virology 2024-02, Vol.98 (2), p.e0177623
• Main Authors: Kim, Jun Yeob, Min, Young Jin, Lee, Min-Hyeok, An, Yea Rim, Ashktorab, Hassan, Smoot, Duane T, Kwon, Sung Won, Lee, Suk Kyeong
• Format: Article
• Language: English
• Subjects: Carcinoma - virology; Cell Line, Tumor; Ceramides - pharmacology; Epstein-Barr Virus Infections - virology; Herpesvirus 4, Human - physiology; Host-Pathogen Interactions; Humans; Mitogen-Activated Protein Kinase 3; Molecular and Cellular Biology; Stomach Neoplasms - virology; Trans-Activators - metabolism; Virus Activation; Virus-Cell Interactions
• ISSN: 0022-538X; 1098-5514; 1098-5514
• DOI: 10.1128/jvi.01776-23

Epstein-Barr virus (EBV) has a lifelong latency period after initial infection. Rarely, however, when the EBV immediate early gene BZLF1 is expressed by a specific stimulus, the virus switches to the lytic cycle to produce progeny viruses. We found that EBV infection reduced levels of various ceramide species in gastric cancer cells. As ceramide is a bioactive lipid implicated in the infection of various viruses, we assessed the effect of ceramide on the EBV lytic cycle. Treatment with C -ceramide (C -Cer) induced an increase in the endogenous ceramide pool and increased production of the viral product as well as BZLF1 expression. Treatment with the ceramidase inhibitor ceranib-2 induced EBV lytic replication with an increase in the endogenous ceramide pool. The glucosylceramide synthase inhibitor Genz-123346 inhibited C -Cer-induced lytic replication. C -Cer induced extracellular signal-regulated kinase 1/2 (ERK1/2) and CREB phosphorylation, c-JUN expression, and accumulation of the autophagosome marker LC3B. Treatment with MEK1/2 inhibitor U0126, siERK1&2, or siCREB suppressed C -Cer-induced EBV lytic replication and autophagy initiation. In contrast, siJUN transfection had no impact on BZLF1 expression. The use of 3-methyladenine (3-MA), an inhibitor targeting class III phosphoinositide 3-kinases (PI3Ks) to inhibit autophagy initiation, resulted in reduced beclin-1 expression, along with suppressed C -Cer-induced BZLF1 expression and LC3B accumulation. Chloroquine, an inhibitor of autophagosome-lysosome fusion, increased BZLF1 protein intensity and LC3B accumulation. However, siLC3B transfection had minimal effect on BZLF1 expression. The results suggest the significance of ceramide-related sphingolipid metabolism in controlling EBV latency, highlighting the potential use of drugs targeting sphingolipid metabolism for treating EBV-positive gastric cancer.IMPORTANCEEpstein-Barr virus remains dormant in the host cell but occasionally switches to the lytic cycle when stimulated. However, the exact molecular mechanism of this lytic induction is not well understood. In this study, we demonstrate that Epstein-Barr virus infection leads to a reduction in ceramide levels. Additionally, the restoration of ceramide levels triggers lytic replication of Epstein-Barr virus with increase in phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and CREB. Our study suggests that the Epstein-Barr virus can inhibit lytic replication and remain latent thro